A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

Paula M. Fracasso,Kerry J. Williams,Ronald C. Chen,Joel Picus,Cynthia X. Ma,Matthew J. Ellis,Benjamin R. Tan,Timothy J. Pluard,Douglas Adkins,Michael Naughton,Janet S. Rader,Matthew A. Arquette,James W. Fleshman,Allison N. Creekmore,Sherry A. Goodner,Lisa P. Wright,Zhanfang Guo,Christine Ryan,Yu Tao,Eliane M. Soares,Shi Rong Cai,Li Lin,Janet Dancey,Michelle A. Rudek,Howard L. McLeod,Helen Piwnica-Worms

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

2011

Purpose UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and pharmacodynamic effects of UCN-01 and irinotecan in patients with resistant solid tumors.

Keywords:

Biochemistry
Topoisomerase
Pharmacodynamics
Pharmacology
Cancer
Camptothecin
Irinotecan
Toxicity
Enzyme inhibitor
Pharmacokinetics
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations